Posts

Posted on

ScanTech Identification Beam Systems, LLC Closes Business Combination with Mars Acquisition Corp. Shares of the New Public Company, ScanTech AI Systems Inc., Will Begin Trading on Nasdaq

  • Business Combination between ScanTech Identification Beam Systems, LLC and Mars Acquisition Corp. closed on January 2, 2025
  • Trading of common stock of the new public company, ScanTech AI Systems Inc., will commence on Nasdaq on January 3, 2025 under the ticker symbol “STAI”

NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) — ScanTech AI Systems Inc. (“ScanTech AI”), today announced the successful closing of its previously announced business combination (the “Business Combination”) between ScanTech Identification Beam Systems, LLC (“ScanTech”), a provider of one of the world’s most advanced non-intrusive “fixed-gantry” CT screening technologies, and Mars Acquisition Corp. (“Mars”) (Nasdaq: MARX), a special purpose acquisition company. Mars shareholders approved the business combination at a special meeting held on December 12, 2024. 

The shares of common stock of the post-combination company, ScanTech AI, are expected to begin trading under the ticker symbol “STAI” on the Nasdaq Global Market on January 3, 2025.

The Business Combination marks a significant step in ScanTech’s evolution. It will enhance ScanTech’s ability to pursue its strategic vision of innovation, adaptability, and customer-centric design. ScanTech AI will remain focused on capturing the potential of an expanding total addressable market, and plans to further expand its portfolio, making technology more accessible and intelligent.

Dolan Falconer, Chief Executive Officer of ScanTech AI, commented, “Our Nasdaq listing marks a pivotal moment in ScanTech’s evolution. As a public company, we are poised to capitalize on new growth opportunities and scale our business globally.”

Karl Brenza, Chief Executive Officer and Chief Financial Officer of Mars, stated, “We are proud to have played a key role in ScanTech’s journey to becoming a public company. ScanTech has demonstrated remarkable operations, and I have no doubt that their relentless focus on innovation and execution will continue to drive ScanTech AI’s success in the public markets. I am excited to continue to play a role in this company’s promising growth story and to have the opportunity to continue working closely together.”

VCL Law LLP served as legal counsel to Mars Acquisition Corp. Ellenoff Grossman & Schole LLP acted as legal counsel to ScanTech Identification Beam Systems, LLC.

About ScanTech AI Systems Inc.

ScanTech AI will continue the business operations of ScanTech, which has developed one of the world’s most advanced non-intrusive ‘fixed-gantry’ CT screening technologies. ScanTech utilizes proprietary artificial intelligence (AI) and machine learning capabilities in its state-of-the-art fixed- gantry CT scanners to accurately and quickly detect hazardous materials and contraband. ScanTech’s ‘fixed-gantry’ CT scanners are engineered to automatically locate, discriminate, and identify threat materials and items of interest at checkpoints in airports, seaports, borders, embassies, corporate headquarters, government & commercial buildings, factories, processing plants, and other facilities where terrorism and prohibited items are a possibility. Whether explosives or contraband, ScanTech’s ‘fixed-gantry’ CT scanners can detect, identify, precisely locate, and discriminate materials of interest hidden inside scanned targets. From suitcases, briefcases, and backpacks to large packages, and parcels, ScanTech has a non-intrusive inspection solution to meet the requirements of a broad range of critical infrastructure industries. 

 Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the U.S. Securities Exchange Act of 1934, as amended (“Exchange Act”), including statements regarding ScanTech AI’s management team’s expectations, hopes, beliefs, intentions, plans, prospects or strategies regarding the future, including possible business combinations, revenue growth and financial performance, product expansion and services. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Additionally, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” “target,” “seek” or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this press release are based on the current expectations and beliefs made by the managements of ScanTech AI, ScanTech and Mars in light of their respective experience and their perception of historical trends, current conditions and expected future developments and their potential effect on ScanTech AI, as well as other factors they believe are appropriate under the circumstances. There can be no assurance that future developments affecting ScanTech AI will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including product and service acceptance, regulatory oversights, research and development success, and that ScanTech AI will have sufficient capital to operate as anticipated. Should one or more of these risks of uncertainties materialize, or should any of the assumptions of ScanTech AI prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Additional factors that could cause actual results to differ are discussed under the heading “Risk Factors” and in other sections of the filings of ScanTech AI (and its predecessor, Mars) with the SEC, and in the current and periodic reports filed or furnished by ScanTech AI (and its predecessor, Mars) from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on the information available to ScanTech AI as of the date hereof, and ScanTech AI assumes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as may otherwise be required under applicable securities laws.

Contact Information: 

ScanTech AI Systems Inc.
Dolan Falconer, CEO
[email protected] 

Investor & Media Relations Contact:

International Elite Capital Inc. 
Annabelle Zhang
+1(646) 866-7928
[email protected]



Posted on

Bank OZK Announces Increase to Quarterly Common Stock Dividend and Announces Preferred Stock Dividend

Fifty-eight consecutive quarters of increased quarterly cash dividend on its common stock

LITTLE ROCK, Ark., Jan. 02, 2025 (GLOBE NEWSWIRE) — Bank OZK (the “Bank”) (Nasdaq: OZK) announced its Board of Directors declared a quarterly cash dividend on the Bank’s common stock of $0.42 per share, up $0.01, or 2.44% from the prior quarter. The common stock dividend is payable on January 21, 2025 to shareholders of record as of January 14, 2025. Bank OZK has increased its quarterly cash dividend on its common stock in each of the last fifty-eight quarters.

The Board of Directors also declared a quarterly cash dividend of $0.28906 per share on the Bank’s 4.625% Series A Non-Cumulative Perpetual Preferred Stock (“Series A Preferred Stock”) (Nasdaq: OZKAP) for the period covering November 15, 2024 through, but excluding February 15, 2025. The Series A Preferred Stock dividend is payable on February 18, 2025, to the holders of record of the Series A Preferred Stock at the close of business on February 3, 2025.

Bank OZK’s consistent track record of increasing its common stock dividend has led to it being included in the S&P High Yield Dividend Aristocrats® index (Ticker: SPHYDA) since January 2018. The index consists of members of the S&P Composite 1500® that have followed a managed-dividends policy of consistently increasing common stock dividends every year for at least 20 years, and that meet minimum float-adjusted market capitalization and liquidity requirements. For more information on the index, visit www.spglobal.com/spdji.


GENERAL INFORMATION


Bank OZK (Nasdaq: OZK) is a regional bank providing innovative financial solutions delivered by expert bankers with a relentless pursuit of excellence. Established in 1903, Bank OZK conducts banking operations in approximately 240 offices in nine states including Arkansas, Georgia, Florida, North Carolina, Texas, Tennessee, New York, California and Mississippi and had $37.44 billion in total assets as of September 30, 2024. For more information, visit www.ozk.com.

The Bank files annual, quarterly and current reports, proxy materials, and other information required by the Securities Exchange Act of 1934 with the Federal Deposit Insurance Corporation (“FDIC”), copies of which are available electronically at the FDIC’s website at https://efr.fdic.gov/fcxweb/efr/index.html and are also available on the Bank’s investor relations website at ir.ozk.com. To receive automated email alerts for these materials please visit https://ir.ozk.com/other/email-alerts to sign up.

Investor Relations Contact:
Media Contact:		       Jay Staley (501) 906-7842
Michelle Rossow (501) 906-3922
     



Posted on

GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer

GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer

Experienced Diagnostics Executive with a Proven Record of Driving Business Growth to Lead Product & Technology, Operations, Medical Affairs, Innovation and More

New Executive Leadership Positions Company for Growth and Scale

STAMFORD, Conn.–(BUSINESS WIRE)–
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Bryan Dechairo as Chief Operating Officer, effective immediately. In the newly created role, Bryan will report to Katherine Stueland, CEO and President, and will serve on the company’s executive leadership team.

As Chief Operating Officer, Bryan will oversee Product & Technology, Operations, Medical Affairs, Innovation, and the Program Management teams at GeneDx. He will be pivotal in driving operational excellence as the company enters the next phase of commercial growth.

“Bryan’s extensive clinical, technical and operational experience and proven ability to lead scalable transformations will play a pivotal role in helping us execute our strategic vision and accelerate the adoption of genomic insights across healthcare,” said Stueland. “As we embark on the next phase of our growth and scale, I am confident Bryan’s leadership will be critical in helping us deliver impactful genomic insights and improve health outcomes for an ever-growing number of patients and families.”

Bryan brings over 30 years of experience in exploratory and commercial diagnostic businesses, driving the development of revenue-generating clinical innovations that enhance patient outcomes. He most recently served as President and CEO of Sherlock Biosciences, where he successfully transformed the company from a research-stage start-up into a commercial operation. Bryan has also held executive leadership roles at prominent diagnostic and pharmaceutical companies, including Pfizer, Myriad Genetics, Assurex, Medco Health and others. Bryan holds a PhD in Human Genetics from the University College of London and a BA in Integrative Biology from the University of California Berkeley.

“GeneDx has built a market-leading position in pediatric genetics and has an incredible opportunity to pave the way for the genomics revolution in healthcare today,” said Dechairo. “With world-class products, advanced AI and the most dynamic minds in the industry, I’m looking forward to supercharging operational excellence to accelerate profitable growth.”

About GeneDx:

GeneDx (Nasdaq: WGS) delivers personalized and actionable health insights to inform diagnosis, direct treatment, and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation services, fueled by the world’s largest, rare disease data sets. For more information, please visit www.genedx.com and connect with us on LinkedIn, Facebook, and Instagram.

[email protected]

[email protected]

KEYWORDS: Connecticut United States North America

INDUSTRY KEYWORDS: Genetics Health Technology Health

MEDIA:

Logo
Logo
Posted on

Cohu to Participate at 27th Annual Needham Growth Conference

Cohu to Participate at 27th Annual Needham Growth Conference

POWAY, Calif.–(BUSINESS WIRE)–
Cohu, Inc. (NASDAQ: COHU), a global supplier of equipment and services optimizing semiconductor manufacturing yield and productivity, today announced that management will participate virtually at the 27th Annual Needham Growth Conference on Thursday, January 9, 2025, with a one-on-one format.

Portfolio managers and analysts should contact their respective banking representatives to schedule a meeting at this conference.

Presentation materials will be made concurrently available on the Investor Relations section of the Company’s website, www.cohu.com.

About Cohu:

Cohu (NASDAQ: COHU) is a global technology leader supplying test, automation, inspection and metrology products and services to the semiconductor industry. Cohu’s differentiated and broad product portfolio enables optimized yield and productivity, accelerating customers’ manufacturing time-to-market. Additional information can be found at www.cohu.com.

For press releases and other information of interest to investors, please visit Cohu’s website at www.cohu.com.

Cohu, Inc.

Jeffrey D. Jones – Investor Relations

858-848-8106

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Semiconductor Engineering Technology Manufacturing Other Manufacturing Hardware

MEDIA:

Logo
Logo
Posted on

Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

CRANBURY, N.J.–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the 43rd Annual J.P. Morgan Healthcare Conference, in San Francisco, California. Gaurav Shah, M.D., Chief Executive Officer, is scheduled to present on Monday, January 13, at 3:45 p.m. PT and host investor meetings throughout the conference.

A webcast of the presentation will be available here and will be posted on the Investors section of the Company’s website.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Rocket’s innovative multi-platform approach allows us to design the optimal gene therapy for each indication, creating potentially transformative options that enable people living with devastating rare diseases to experience long and full lives.

Rocket’s lentiviral (LV) vector-based hematology portfolio consists of late-stage programs for Fanconi Anemia (FA), a difficult-to-treat genetic disease that leads to bone marrow failure (BMF) and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia.

Rocket’s adeno-associated viral (AAV) vector-based cardiovascular portfolio includes a late-stage program for Danon Disease, a devastating heart failure condition resulting in thickening of the heart, an early-stage program in clinical trials for PKP2-arrhythmogenic cardiomyopathy (ACM), a life-threatening heart failure disease causing ventricular arrhythmias and sudden cardiac death, and a pre-clinical program targeting BAG3-associated dilated cardiomyopathy (DCM), a heart failure condition that causes enlarged ventricles.

For more information about Rocket, please visit www.rocketpharma.com and follow us on LinkedIn, YouTube, and X.

Rocket Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements concerning Rocket’s future expectations, plans and prospects that involve risks and uncertainties, as well as assumptions that, if they do not materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this release are forward-looking statements. You should not place reliance on these forward-looking statements, which often include words such as “could,” “believe,” “expect,” “anticipate,” “intend,” “plan,” “will give,” “estimate,” “seek,” “will,” “may,” “suggest” or similar terms, variations of such terms or the negative of those terms. These forward-looking statements include, but are not limited to, statements concerning Rocket’s expectations regarding the safety and effectiveness of product candidates that Rocket is developing to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Danon Disease (DD) and other diseases, the expected timing and data readouts of Rocket’s ongoing and planned clinical trials, the expected timing and outcome of Rocket’s regulatory interactions and planned submissions, including the timing and outcome of the FDA’s review of the additional CMC information that Rocket will provide in response to the FDA’s request, the safety, effectiveness and timing of pre-clinical studies and clinical trials, Rocket’s ability to establish key collaborations and vendor relationships for its product candidates, Rocket’s ability to develop sales and marketing capabilities or enter into agreements with third parties to sell and market its product candidates, Rocket’s ability to expand its pipeline to target additional indications that are compatible with its gene therapy technologies, Rocket’s ability to transition to a commercial stage pharmaceutical company, and Rocket’s expectation that its cash, cash equivalents and investments will be sufficient to funds its operations into 2026. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket’s dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, unexpected expenditures, Rocket’s competitors’ activities, including decisions as to the timing of competing product launches, pricing and discounting, Rocket’s ability to develop, acquire and advance product candidates into, enroll a sufficient number of patients into, and successfully complete, clinical studies, the integration of new executive team members and the effectiveness of the newly configured corporate leadership team, Rocket’s ability to acquire additional businesses, form strategic alliances or create joint ventures and its ability to realize the benefit of such acquisitions, alliances or joint ventures, Rocket’s ability to obtain and enforce patents to protect its product candidates, and its ability to successfully defend against unforeseen third-party infringement claims, as well as those risks more fully discussed in the section entitled “Risk Factors” in Rocket’s Annual Report on Form 10-K for the year ended December 31, 2023, filed February 27, 2024 with the SEC and subsequent filings with the SEC including our Quarterly Reports on Form 10-Q. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Media & Investors

Meg Dodge

[email protected]

Media

Kevin Giordano

[email protected]

Investors

Brooks Rahmer

[email protected]

KEYWORDS: California New Jersey United States North America

INDUSTRY KEYWORDS: Oncology Health Health Technology Genetics Other Health Pharmaceutical Biotechnology

MEDIA:

Logo
Logo
Posted on

PMGC Holdings Inc. Following Skincare Subsidiary Sale, Embarks on Bold Growth Strategy

Divestiture Highlights Strategic Plans on Potential High-Impact Acquisitions

Strategic Divestment Reduces Cash Burn and Enhances Operational Efficiency

NEWPORT BEACH, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) — PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: ELAB) today announced its commitment to accelerating shareholder value creation and market leadership following the sale of its skincare subsidiary, Elevai Skincare. This strategic divestiture marks a significant milestone in PMGC’s journey as a diversified holding company.

The sale was executed to maximize immediate financial benefit while securing future upside through structured royalties and milestone payments. It has notably strengthened PMGC’s balance sheet, reduced operational losses, and paved the way for new opportunities that align with the company’s long-term vision.

Strategic Rationale: Think Bigger, Act Bold

The divestiture underscores PMGC’s strategy to focus on acquiring transformative assets and businesses that deliver substantial growth and shareholder value. This sale frees the Company to look for bigger opportunities. Executive management’s goal is not incremental improvement but exponential growth through strategic acquisitions and steadfast execution.

Key Financial and Operational Highlights Post Sale

  • Burn Rate Reduction: By eliminating a loss-generating subsidiary, PMGC ensures a leaner and more focused operational framework.
  • Strengthened Financials: PMGC will receive approximately $1.1 million in Carmell Corporation stock and retains a lucrative 5% royalty on skincare revenues over the next five years, alongside milestone payment opportunities​.
  • Growth Capital: Resources will now be channeled into high-potential assets, leveraging PMGC’s drive and expertise in creating shareholder value.

Why It Matters to Shareholders

This move demonstrates PMGC’s agility in adapting to market opportunities and its unwavering commitment to delivering shareholder value. The sale of Elevai Skincare is a step toward creating a portfolio of assets that reflects the company’s expansive vision and ambition.

For investors, this signals a moment of transition and opportunity. As PMGC positions itself to seize larger, more impactful opportunities, shareholders can look forward to the potential for increased returns, reduced risk, and sustainable growth.

Looking Ahead: Growth, Diversification, and Opportunity

PMGC is actively exploring accretive acquisitions and licensing opportunities in sectors poised for significant growth. The Company is focused on identifying undervalued assets and businesses that align with a vision of building a diversified and growth-oriented holding company.

PMGC Holdings Inc. will continue to expand its company portfolio with a focus on innovation, growth, and shareholder value creation. Current subsidiaries include:

Elevai Biosciences: a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. Our lead asset, EL-22, is leveraging an engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit www.elevaibio.com.

Elevai Research: a research and development subsidiary, currently utilizing Canadian research grants and partnering with leading Canadian Universities to push the boundaries of innovation

PMGC Capital LLC: a multi-strategy investment vehicle engaging in investing, lending, and seeking diversified investment opportunities across various markets.

The current subsidiaries and pending opportunities underscore PMGC’s focus on thinking bigger and its drive to build a growth-oriented portfolio.

About PMGC Holdings Inc.

PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. Currently, our portfolio consists of three wholly owned subsidiaries: Elevai Biosciences Inc., Elevai Research Inc., and PMGC Capital LLC. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC Holdings’ filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

IR Contact:


[email protected]



Posted on

ISG Advisors Recognized as 2024 HRO Today Superstars

ISG Advisors Recognized as 2024 HRO Today Superstars

Stacey Cadigan and Debora Card honored by magazine as top HRO thought leaders

STAMFORD, Conn.–(BUSINESS WIRE)–HRO Today has named two advisors from Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm, as 2024 HRO Today Superstars for helping enterprises navigate an ever-evolving business landscape and establish workplace models that balance productivity needs with employee expectations.

Stacey Cadigan, partner, was named an HRO Today Superstar for the ninth consecutive year, and Debora Card, partner, was honored for the eleventh consecutive year, both in the Thought Leaders category. HRO Today defines its Superstars as those who are “leading through business disruption.”

“In an ongoing climate of cost optimization, HR has been tasked with supporting enterprise agility to meet business demands and ensure employees stay productive and engaged,” said Todd Lavieri, vice chairman and president, ISG Americas and Asia Pacific. “Congratulations to Stacey and Deb on this well-deserved recognition for their work to help clients identify, implement and leverage the technologies that can engage people, guide processes and deliver meaningful experiences.”

“After more than four years of trials and rapid change, 2024 was a year of ambition,” the editors of HRO Today said in announcing the awards. “Despite the obstacles and uncertainty in their path, these HR leaders pushed forward, deepened their understanding of new technological advancements, renewed their focus on employee engagement and wellness, and prepared for the challenges still to come.”

ISG HR Technology and Outsourcing Solutions is a leading independent advisor on all aspects of HR transformation, working closely with clients as they create a business case for technology investment, select the best platform and services for their needs and manage organizational and process change.

Cadigan leads the ISG HCM and Enterprise Transformation business, and has particular expertise in HR outsourcing, HR technology and talent management. She co-authors the biennial ISG Survey on Industry Trends in HR Technology and Service Delivery report, which tracks how market trends are evolving based on prior research and examines the maturity of organizations as they make their way along the digital transformation journey. The next report will be published in the first half of 2025.

Card has 30 years’ experience in HR and benefits administration shared services and outsourcing to help clients define and implement their HR/benefits technology and service delivery strategies.

Awards are given in three categories: Providers, Practitioners, and Thought Leaders (consultants/advisors/analysts/academics/investors). Superstars were nominated externally through an online tool and by the HRO Today staff. To see the list of honorees in the third category, visit this webpage. A complete list of all winners is available here.

About HRO Today and HRO Today Global

HRO Today and HRO Today Global are the properties of SharedXpertise Media and offer the broadest and deepest reach available anywhere in the HR industry. Our magazines, web portals, research, e-newsletters, events, and social networks reach senior-level HR decision-makers with rich, objective, game-changing content. Our No. 1 strength is our reach. HR leaders rely heavily on the HRO Today’s Baker’s Dozen rankings across six different categories when selecting an HR service provider.

About ISG

ISG (Information Services Group) (Nasdaq: III) is a leading global technology research and advisory firm. A trusted business partner to more than 900 clients, including more than 75 of the world’s top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including AI, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,600 digital-ready professionals operating in more than 20 countries—a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry’s most comprehensive marketplace data. For more information, visit www.isg-one.com.

Press Contacts:

Will Thoretz, ISG

+1 203 517 3119

[email protected]

Julianna Sheridan, Matter Communications for ISG

+1 978 518 4520

[email protected]

KEYWORDS: Connecticut United States North America

INDUSTRY KEYWORDS: Software Mobile/Wireless Networks Internet Professional Services Electronic Design Automation Data Management Technology Security Human Resources Other Technology Consulting

MEDIA:

Logo
Logo
Posted on

Alset Inc. Announces $1.5 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

BETHESDA, MD, Jan. 02, 2025 (GLOBE NEWSWIRE) — Alset Inc. (NASDAQ: AEI) (the “Company”), a diversified company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities and consumer products with operations in the United States, Singapore, Hong Kong and South Korea, today announced that it has entered into definitive agreements in a registered direct offering with institutional investors for the purchase and sale of approximately $1.5 million of shares of common stock and pre-funded warrants at a price of $1.00 per share of common stock. The entire transaction has been priced at the market under Nasdaq rules.

The offering consists of the sale of 1,500,000 shares of common stock (or pre-funded warrants). The public offering price per share of common stock is $1.00 (or $0.999 for each pre-funded warrant, which is equal to the public offering price per share of common stock to be sold in the offering minus an exercise price of $0.001 per pre-funded warrant). The pre-funded warrants will be immediately exercisable and may be exercised at any time until exercised in full. For each pre-funded warrant sold in the offering, the number of shares of common stock in the offering will be decreased on a one-for-one basis.

Aggregate gross proceeds to the Company are expected to be approximately $1.5 million. The transaction is expected to close on or about January 3, 2025, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offering, together with its existing cash, for general corporate purposes and working capital.

Aegis Capital Corp. is acting as exclusive placement agent for the offering. Sichenzia Ross Ference Carmel LLP is acting as U.S. counsel to the Company. Kaufman & Canoles, P.C. is acting as U.S. counsel to Aegis Capital Corp.

The registered direct offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-264234) previously filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on May 5, 2022. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at [email protected], or by telephone at +1 (212) 813-1010.

Interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About
Alset Inc.

Alset Inc. is a diversified company executing on its vision to accelerate sustainable healthy living with a focus on the development of EHome communities and other property development, financial services, digital transformation technologies, biohealth activities and consumer products. Through its operating subsidiaries, Alset’s mission is to provide a healthy living ecosystem that drives long-term exponential growth, building liquidity and value for shareholders. For more information, please visit: www.alsetinc.com.

Forward-Looking Statements

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements relating to the completion of the offering, the satisfaction of customary closing conditions and the use of proceeds from the offering, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance.  These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Investor Contact: Alset Inc., 4800 Montgomery Lane, Suite 210, Bethesda, MD 20814 Email: [email protected]



Posted on

Cinemark Celebrates its First “Bring Your Own Bucket” Day for National Popcorn Day on Jan. 19

Cinemark Celebrates its First “Bring Your Own Bucket” Day for National Popcorn Day on Jan. 19

In addition to its $5 BYOBucket promotion, Cinemark is honoring the cinematic snack with $5 XL popcorn in theaters, social sweepstakes and discounts on gift cards

PLANO, Texas–(BUSINESS WIRE)–Cinemark Holdings, Inc. (NYSE: CNK), one of the largest and most influential theatrical exhibition companies in the world, invites popcorn lovers everywhere to grab their favorite bucket and head to their local Cinemark theater to celebrate the chain’s first-ever “Bring Your Own Bucket” day in honor of National Popcorn Day on Sunday, Jan. 19. In addition to enjoying heaps of the buttery goodness while showing off their favorite vessels, popcorn lovers can celebrate the annual holiday with $5 XL popcorn at all Cinemark theaters, a social sweepstakes and a special discount on gift cards, providing endless opportunities to enjoy that bingeworthy popcorn. More information on Cinemark’s National Popcorn Day celebrations can be found at Cinemark.com/popcornday.

“National Popcorn Day is one of the best days of the year at Cinemark, and for popcorn lovers everywhere. We are thrilled to mark this year’s celebration with our first ever ‘Bring Your Own Bucket’ event, in addition to limited time sweepstakes and promotions,” said David Haywood, Cinemark SVP Food & Beverage. “Popcorn has always been the star of movie theater concessions, though popcorn vessels have become an award-worthy supporting actor. We are excited for everyone to get creative with this campaign and show off their choice of container while enjoying the iconic snack alongside a great film.”

BYOBucket

Whether it’s an iconic film-specific collectible bucket, the favorite snack bowl that has been passed down from generation to generation, or a creative DIY art project, Cinemark invites all popcorn lovers to bring the containers to their local theater to receive a $5 fill up of warm, bingeworthy popcorn, only on Sunday, Jan. 19. Everyone is invited to participate, no movie ticket required. As long as the container is clean and does not exceed 400 ounces, Cinemark will fill it to the brim with crisp, freshly popped kernels. Even those without a from-home container can get in on the fun with $5 XL popcorn at all Cinemark locations on National Popcorn Day.

For those still in need of a cinematic container worthy of the celebration, shop.cinemark.com has eye-catching buckets from some of the recent big releases. And, everyone is encouraged to show off their buckets of choice by tagging @Cinemark on social channels.

Once everyone’s favorite buckets are poppin’ with the salty snack, guests can sit back and relax in comfortable seats while enjoying several captivating films on the larger-than-life screens, including Wolf Man,Mufasa: The Lion King,Sonic the Hedgehog 3, Nosferatu and more.

Golden Sweeps and Promotions

Cinemark is making sure that celebration of the iconic cinematic snack goes beyond buckets. On Jan. 19 only, all who follow Cinemark’s official Instagram account (@Cinemark) and tag three friends in the comments of the National Popcorn Day sweepstakes post will be entered to win a free large popcorn. The exhibitor will also be buttering up movie lovers with 10 percent off all online gift card orders. With so many great films coming to theaters in 2025, including Captain America: Brave New World (Feb. 14), Mission Impossible: Final Reckoning (May 23), Karate Kid: Legends (June 30), Ballerina (June 6), Jurassic World: Rebirth (July 2), Superman (July 11), and so much more, Cinemark’s special discounts on gift cards for National Popcorn Day will ensure cinephiles can splurge on every part of the moviegoing experience, including concessions.

More Cinematic at Cinemark

Alongside the sight and sound technology that cannot be replicated at home, Cinemark gives moviegoers the star treatment with its fan-favorite loyalty program, convenient concessions ordering and online merchandise store. Cinemark Movie Rewards awards movie lovers with one point for every dollar spent at a Cinemark theater, and fans can level up to Cinemark Movie Club, a monthly membership program with star-studded benefits such as a monthly movie credit with no rollover and no expiration, a 20 percent discount on concessions and more. Snacking has never been easier at Cinemark, with advanced mobile ordering for easy pick up within the theater and third-party delivery partnerships with DoorDash, Grubhub and Uber Eats, to ensure customers can enjoy their favorite movie theater concessions whenever and wherever the craving hits. And, shopcinemark.com makes it simple for super fans to purchase great movie merchandise at any time.

For full details about the Cinemark moviegoing experience, visit Cinemark.com or download the Cinemark app. Click HERE for general Cinemark images and b-roll.

About Cinemark Holdings, Inc.

Cinemark Holdings, Inc. (NYSE: CNK) provides extraordinary out-of-home entertainment experiences as one of the largest and most influential theatrical exhibition companies in the world. Based in Plano, Texas, Cinemark makes every day cinematic for moviegoers across nearly 500 theaters and more than 5,500 screens, operating in 42 states in the U.S. (306 theaters; 4,282 screens) and 13 South and Central American countries (193 theaters; 1,398 screens). Cinemark offers guests superior sight and sound technology, including Barco laser projection and Cinemark XD, the world’s No. 1 exhibitor-branded premium large format; industry-leading penetration of upscale amenities such as expanded food and beverage offerings, Luxury Lounger recliners and D-BOX motion seats; top-notch guest service; and award-winning loyalty programs such as Cinemark Movie Club. All of this creates an immersive environment for a shared, entertaining escape, underscoring that there is no place more cinematic than Cinemark. For more information, visit https://ir.cinemark.com.

Media:

Julia McCartha

[email protected]


Investors:

Chanda Brashears

[email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Women Entertainment Men General Entertainment Family Food/Beverage Film & Motion Pictures Consumer Retail

MEDIA:

Logo
Logo
Posted on

loanDepot Featured in Orange County Business Journal’s 2024 “Companies That Care” Report

loanDepot Featured in Orange County Business Journal’s 2024 “Companies That Care” Report

Celebrates the extraordinary contributions of businesses making a difference in the Orange County, Calif. community.

IRVINE, Calif.–(BUSINESS WIRE)–
loanDepot, Inc. (“LDI” or “Company”) (NYSE: LDI), a leading provider of products and services that power the homeownership journey, was featured in the Orange County Business Journal’s (OCBJ) 2024 “Companies That Care” report, recognizing extraordinary contributions of businesses making a difference in the Orange County, Calif., community.

With a culture deeply rooted in volunteerism and community support, loanDepot earned a place on the list for its ongoing support of non-profit organizations that align with its mission in Orange County, where the company is headquartered.

“At loanDepot, we’re driven by a commitment to helping families achieve their homeownership and financial goals, while fostering a culture of giving back—it’s deeply embedded in our DNA,” said loanDepot Chief Human Resources Officer Melanie Graper. “Whether through donations, volunteerism, advocacy, or partnerships with non-profit organizations, our team is dedicated to making a positive and lasting difference in the lives of our Orange County neighbors and communities across the country—and we’re honored to be recognized among the ‘Companies That Care’ for 2024.”

As part of its presenting sponsorship of Habitat for Humanity’s “Home is the Key” advocacy campaign designed to help unlock equitable homeownership and build inclusive communities, loanDepot employees and executives volunteered in Southern California, helping to construct a multi-family home in Los Angeles along with building playhouses for three families in Orange County. Additionally, Martell uses his influence to advocate for solutions to the critical housing challenges facing communities today, including the importance of equitable access to affordable and sustainable homeownership.

As one of the country’s top providers of VA loans, loanDepot is deeply committed to serving the military community. loanDepot Founder and Board Chair Anthony Hsieh created the War Heroes on Water (WHOW) sportfishing tournament in 2018 to serve the needs of combat-wounded veterans, which draws deep Team loanDepot support annually – and has raised more than $7 million to date. The company supports the Marine Corps Scholarship Foundation, helping to provide need-based scholarships to the children of active-duty and prior service Marines and Navy Corpsmen—and sponsors “Military Appreciation Day” at the HOAG Classic in Newport Beach.

loanDepot also supports the American Heart Association’s (AHA) Go Red for Women campaign, which funds research and raises awareness of cardiovascular disease and stroke in women, and champions STEM education through a mentorship program for young women. Several other area organizations have special ties to the company’s leadership and employees, including the American Red Cross of Orange County, Operation HOPE and Second Harvest Food Bank of Orange County.

About loanDepot

At loanDepot (NYSE: LDI), we know home means everything. That’s why we are on a mission to support homeowners with a suite of products and services that fuel the American Dream. Our portfolio of digital-first home purchase, home refinance and home equity lending products make homeownership more accessible, achievable, and rewarding, especially for the increasingly diverse communities of first-time homebuyers we serve. Headquartered in Southern California with local market offices nationwide, loanDepot and its sister real estate and home services company, mellohome, are dedicated to helping customers put down roots and bring dreams to life – all while building stronger communities and a better tomorrow.

Media Contact

Jonathan Fine

VP, Public Relations

(781) 248-3963

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Construction & Property Finance Fintech Banking Professional Services Philanthropy Fund Raising Foundation Other Philanthropy Residential Building & Real Estate

MEDIA:

Logo
Logo